Title Assistant Professor of Medicine Institution Brigham and Women's Hospital Address Brigham and Women's Hospital 75 Francis St Boston MA 02115
|
|
Biography
University of British Columbia, Canada | | 01/2015 | Tissue regeneration |
Oregon Health and Science University, US | Ph.D. | 11/2008 | Molecular physiology |
Biogen, US | | 10/2016 | Tissue injury and regeneration |
2004 - 2005
Fogarty International Scholarship
2001 - 2002
Undergraduate Student Research Scholarship
2019 - 2019
Department of Medicine Chair's Research Award
Overview
Biomedical researcher with expertise in mechanisms of tissue regeneration and stem cell biology
Research
The research activities and funding listed below are automatically derived from
NIH ExPORTER and other sources, which might result in incorrect or missing items.
Faculty can
login
to make corrections and additions.
-
(Dario Lemos)
Jul 1, 2023 - Jun 30, 2024
Brigham Research Institute-Fund to Sustain Research Excellence
Mechanisms of renal angiomyolipoma in Tuberous Sclerosis Complex
Role Description: A majority of patients with Tuberous Sclerosis Complex (TSC) develop kidney tumors known as angiomyolipomas (AMLs) that can cause renal insufficiency and spontaneous life-threatening bleedings, resulting in premature death. The mechanisms of AML initiation and growth remain unknown, partly because of the lack of proper tools to study these tumors in the laboratory. We will investigate the origin and formation of AMLs using miniature AMLs recreated in our laboratory using patient-derived induced pluripotent stem cells, with which we will examine individual cells with the goal of identifying targets for future therapies.
-
(Dario Lemos)
Jul 1, 2023 - Jun 30, 2024
Paul Teschan Research Fund
Secondary use of induced pluripotent stem cells for generation of kidney tissues - Novel therapies for Tuberous Sclerosis Complex-Associated renal angiomyolipoma
Role Description: Angiomyolipoma (AML) growth can cause renal insufficiency and lead to chronic kidney failure in patients with Tuberous Sclerosis Complex (TSC). Everolimus is the main treatment for AML, however orally administered free drug has only 40%-50% efficacy in reducing tumor size and can cause multiple adverse effects. In this project we will use AML organoids generated from induced pluripotent stem cells, as the experimental platform to identify mechanisms of tumor resistance and to test a novel nanocarrier-based approach for AML-targeted drug delivery as a pharmacologic strategy to increase anti-tumor efficacy and reduce adverse effects.
-
R01CA269583
(Dario Lemos)
Jun 1, 2023 - May 31, 2028
Elucidation Tumor Resistance Mechanisms in Tuberous Sclerosis Complex-Associated Renal Angiomyolipoma for the Design of Novel Nanotherapies
Role Description: A majority of patients with Tuberous Sclerosis Complex (TSC) develop kidney angiomyolipomas (AMLs) that can cause renal insufficiency and life-threatening spontaneous hemorrhages, for which the only current therapy is everolimus. Everolimus has limited anti-tumor efficacy, and tumor re-growth frequently occurs after treatment is interrupted due to side effects. In order to investigate the mechanisms of tumor resistance to everolimus therapy, we have generated AML tissues from patient-derived induced pluripotent stem cells, which we will use to test novel therapies with increased efficacy.
-
R01DK124301
(LEMOS, DARIO)
Apr 9, 2020 - Mar 31, 2023
Inflammatory Signaling in Kidney Stromal Cells Driving Interstitial Fibrosis
Role Description: A majority of patients with Tuberous Sclerosis Complex (TSC) develop kidney angiomyolipomas (AMLs) that can cause renal insufficiency and life-threatening spontaneous hemorrhages, for which the only current therapy is everolimus. Everolimus has limited anti-tumor efficacy, and tumor re-growth frequently occurs after treatment is interrupted due to side effects. In order to investigate the mechanisms of tumor resistance to everolimus therapy, we have generated AML tissues from patient-derived induced pluripotent stem cells, which we will use to test novel therapies with increased efficacy.
-
R21AG058159
(LEMOS, DARIO)
Jul 1, 2018 - Mar 31, 2020
Detection of aging mechanisms of nephron degeneration using nanoscale pathology
Role Description: The goal of this project is to test, in collaboration with the MIT Media Lab, the use of Expansion Microscopy for the early detection of aging-associated changes in the nephron microenvironment in relation to the adoption of a secretory senescent phenotype in epithelial cells of the proximal tubule
Role: Principal Investigator
-
(Dario R. Lemos)
May 18, 2018 - Nov 29, 2019
Bioengineered tissues for kidney regeneration in acute and chronic kidney injury
Role Description: The goal of these studies is to test a series of procedures for the establishment of a kidney regeneration protocol using progenitor cells derived from human pluripotent stem cells.
Role: Principal Investigator
-
(Fabio M. V. Rossi)
Sep 1, 2012 - Sep 1, 2015
Heart and Stroke Foundation of Canada
Characterization and therapeutic potential of fibroadipogenic progenitors
Role Description: The main goal was to study the interactions between adipocyte progenitors and inflammatory innate immune cells in the context of metabolic syndrome. Specifically, the aim to study how secretion of TGF? by anti-inflammatory macrophages could regulate adipose depot growth by stimulating the proliferation of progenitor cells, supporting hyperplasia over hypertrophy, and therefore exerting a beneficial effect. The results were published in the journals Nature Medicine and Stem Cells.
Role: Co-Investigator (Co-author)
-
(Dario Lemos)
Jul 1, 2010 - Jul 1, 2011
Canadian Institutes of Health Research
Effect of Imatinib mesylate (Gleevec®) on sarcopenia-associated fibrofatty muscle degeneration
Role Description: The goal of the study was to explore the effect of Gleevec treatment on aging-associated ectopic intramuscular connective tissue accumulation in mice. The results were published in the journal Stem Cell Research.
Role: Principal Investigator
Bibliographic
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.